Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort

Cancer Immunology Research
J Bryan IorgulescuTimothy R Smith

Abstract

The successes of checkpoint blockade immunotherapy (CBI) and BRAFV600-targeted therapy trials have generated substantial promise for revolutionizing the management of patients with advanced melanoma. However, because early clinical trials of CBIs and BRAFV600-targeted therapy either excluded or included disproportionately fewer cases of melanoma brain metastases (MBMs), the survival benefit of these novel therapies for MBM remains unknown. We, therefore, evaluated the characteristics, management, and overall survival (OS) of patients who presented with cutaneous MBMs during 2010 to 2015 using the National Cancer Database, which comprises 70% of all newly diagnosed U.S. cancers. OS was analyzed with risk-adjusted proportional hazards and compared by Kaplan-Meier techniques. We found that 2,753 (36%) of patients presenting with stage 4 melanoma had MBMs. Following the 2011 FDA approvals for CBI and BRAFV600-targeted therapy, MBM patients demonstrated a 91% relative increase in 4-year OS to 14.1% from 7.4% preapproval (P < 0.001). Postapproval, the proportion of MBM patients who received CBI rose from 10.5% in 2011 to 34.0% in 2015 (P < 0.001). Initial CBI in MBM patients displayed an improved median and 4-year OS of 12.4 months (...Continue Reading

References

Feb 22, 1990·The New England Journal of Medicine·R A PatchellB Young
Aug 4, 2007·The Oncologist·April F Eichler, Jay S Loeffler
May 18, 2011·Radiation Oncology·Giuseppe MinnitiRiccardo Maurizi Enrici
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Oct 21, 2011·Current Oncology Reports·Lakshmi NayakPatrick Y Wen
Feb 24, 2012·The New England Journal of Medicine·Jeffrey A SosmanAntoni Ribas
Mar 30, 2012·The Lancet Oncology·Kim MargolinF Stephen Hodi
Sep 24, 2013·Lancet·Alexander M M EggermontCaroline Robert
Oct 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patrick A OttCaroline Robert
Apr 30, 2014·Cancer Immunology Research·Christopher A BarkerJedd D Wolchok
Oct 3, 2014·Journal of Neuro-oncology·Naamit K GerberKathryn Beal
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Mar 11, 2015·International Journal of Radiation Oncology, Biology, Physics·Ana P KiessKathryn Beal
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Apr 22, 2015·The New England Journal of Medicine·Michael A PostowF Stephen Hodi
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Dec 30, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K A AhmedG T Gibney
Jan 26, 2016·Current Opinion in Oncology·Simone M GoldingerPaul Nathan
Feb 13, 2017·Cancer Treatment Reviews·Sandro PasqualiSimone Mocellin
Feb 28, 2017·JAMA Oncology·Daniel J BoffaDavid P Winchester
Aug 18, 2017·International Journal of Radiation Oncology, Biology, Physics·Noelle L WilliamsWenyin Shi

❮ Previous
Next ❯

Citations

Mar 12, 2019·CNS Oncology·Maya HararyJ Bryan Iorgulescu
Apr 17, 2019·Journal of Neuro-oncology·Vasileios K KavouridisTimothy R Smith
Oct 5, 2019·International Journal of Cancer. Journal International Du Cancer·Mark P van OpijnenEllen H W Kapiteijn
Jul 6, 2020·International Forum of Allergy & Rhinology·Daniella KlebanerFarhoud Faraji
Aug 14, 2020·Epigenomics·Danielle R BondHeather J Lee
Jul 20, 2019·BioMed Research International·Yen-Bin HsuMing-Ying Lan
Mar 17, 2019·International Journal of Molecular Sciences·Malcolm LimJodi M Saunus
May 11, 2019·Dermatology Research and Practice·Susanne J RogersStephan B Bodis
Sep 3, 2020·Nature Reviews. Neurology·Riccardo SoffiettiRoberta Rudà
Mar 22, 2020·Current Cardiology Reports·Karina BruestleBettina Heidecker
Sep 27, 2019·Neuro-oncology Practice·Jawad FaresMaciej S Lesniak
Apr 29, 2021·Neuro-oncology·Nayan LambaAyal A Aizer
Sep 9, 2021·International Reviews of Immunology·Shane PrenzlerThomas Haselhorst
Oct 31, 2021·Drug Delivery and Translational Research·Christine P CarneyAnthony J Kim
Dec 22, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A VogelbaumDavid Schiff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.